ClinicalTrials.gg
RecruitingNCT07349810Updated Jan 21, 2026

Post Operative Infusion Pump Pain Study

A Phase 4 interventional study of Bupivacaine 0.5% Injectable Solution and Ropivacaine 0.2% Injectable Solution in Post Operative Pain, sponsored by Rutgers, The State University of New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Rutgers, The State University of New Jersey · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.

Planned enrollment
71st of 184
80 · median 70
Started
2026
with 4 others
Phase 4
84 of 184
7 open now
Primary completion
2026-06
later than 8 of 21 live
Registered
180th of 184
by date

Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 71st largest by planned enrollment, is one of 5 that started in 2026, is one of 84 in phase 4, reaches primary completion later than 8 of the 21 other live ones, and was the 180th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About ropivacaine

Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies testing ropivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign.

Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups.

Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

03

Conditions studied

  • Post Operative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • ACL reconstruction
  • Open shoulder labrum or rotator cuff surgery
  • Arthroscopic rotator cuff repair
  • Proximal or distal patellar realignment surgery
  • Open knee arthrotomy cases - Inside out meniscus repair, OCA, MAT

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years
  • of greater than 40 kg/m2
  • class 4 physical status or greater
  • History of drug or alcohol abuse
  • Chronic opioid use/pain management doctor
  • Allergy to bupivacaine, ropivacaine or pharmacologic analogs
  • Any coagulation disorders
  • Existing nerve injury
  • Severe bronchopulmonary disease
  • Pregnant patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Post-Operative: Continuous ropivacaine via Ambit pump

    Postoperatively, infusion pump reservoirs will contain 0.20% ropivacaine and infused via the Ambit pump (8cc/hr for knees, 6cc/hr for shoulders).

    Drug: Bupivacaine 0.5% Injectable Solution · Drug: Ropivacaine 0.2% Injectable Solution · Device: ambIT Infusion Pump

  • Active comparator
    Pre-Operative: Liposomal bupivacaine (Exparel)

    A single-shot of Liposomal Bupivicaine (Exparel) will be administered pre-operatively

    Drug: Bupivacaine 0.5% Injectable Solution · Drug: 1.3% liposomal bupivacaine (Exparel)

Interventions

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Preoperatively, a nerve block consisting of 0.5% bupivacaine will be given to ALL patients * A bolus of 20cc will be used for saphenous nerve blocks for knee surgeries * A bolus of 15cc will be used for interscalene nerve blocks for shoulder surgeries

  • DrugRopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Post-operative continuous infusion

  • DrugLiposomal BupivacaineStudies of Liposomal BupivacaineLiposomal Bupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pre-operative infiltrative of 10cc of 1.3% liposomal bupivacaine (Exparel)

  • DeviceambIT Infusion Pump

    A pain pump provides intermittent delivery of medication to manage post-surgery pain.

06

What researchers measure

Primary outcomes

  1. The effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period

    Compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. NPRS score difference of approximately 1.5 +/- 1 (approximately 2 points) to detect clinically significant difference in pain score.

    Time frame: Postoperative days 0, 1,2,3,4,7,10, 14

Secondary outcomes

  1. Evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups

    use of narcotic and other analgesic pain medication throughout the 14 day postoperative period

    Time frame: Postoperative period through day 14

  2. Safety Outcomes

    Evaluate the rates of catheter site infection, extravasation, pump malfunction

    Time frame: Postoperative period through day 14

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trail, after deidentification.

Supporting information: Study protocol

Time frame: Immediately following publication. No end date.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2026, 5 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 5 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 20, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07349810
Responsible party
Charles Gatt, MD (Chair of the Department of Orthopaedic Surgery at Rutgers Robert Wood Johnson, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Jan 20, 2026
Start date
Jan 1, 2026
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 21, 2026

Study contacts

Charles Gatt, MD
Contact
cjgatt85@gmail.com
732-537-0909

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion